NAGLU and early-onset autosomal dominant Alzheimer disease: A significant increase in NAGLU activity in four cell lines in the presence of glycomimetic MK 8719, a molecule tested in a Phase 1 study in healthy volunteers to treat Alzheimer's disease, was demonstrated.